• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Arrowhead Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    9/2/25 4:02:33 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARWR alert in real time by email
    arwr-20250902
    0000879407FALSE00008794072025-09-022025-09-02

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    FORM 8-K
    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(D) OF
    THE SECURITIES EXCHANGE ACT OF 1934
    September 2, 2025
    Date of Report
    (Date of earliest event reported)
    Arrowhead Pharmaceuticals, Inc.
    (Exact name of registrant as specified in its charter)
    Delaware001-3804246-0408024
    (State or other jurisdiction
    of incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)
    177 E. Colorado Blvd, Suite 700, Pasadena, CA 91105
    (Address of principal executive offices, including Zip Code)
    (626) 304-3400
    (Registrant’s telephone number, including area code)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common Stock, par value $0.001 per share ARWR The Nasdaq Global Select Market
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 1.01 Entry into a Material Definitive Agreement

    Exclusive licensing and collaboration agreement

    On September 2, 2025, Arrowhead Pharmaceuticals, Inc. (the “Company”) entered into an Exclusive License and Collaboration Agreement (the “Agreement”) with Novartis Pharma AG, a company organized under the laws of Switzerland (“Novartis”).

    Under the Agreement, Novartis will receive an exclusive license for ARO-SNCA, a preclinical stage investigational RNA interference (“RNAi”) therapeutic being developed by the Company as a potential treatment of Parkinson’s Disease, and other synucleinopathies, and for other additional collaboration targets utilizing the Company’s proprietary Targeted RNAi Molecule platform.

    The Company will conduct and complete all activities through the preclinical stages of ARO-SNCA, and Novartis will be wholly responsible for clinical development, manufacturing, and commercialization activities. The Company will receive $200 million as an upfront payment and is eligible to receive up to $2 billion in potential development, regulatory and sales milestones, and is further eligible to receive tiered royalties up to the low double digits on net product sales.

    The transactions contemplated under the Agreement are subject to customary closing conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

    The description of the Agreement contained herein does not purport to be complete and is qualified in its entirety by reference to the complete text of the Agreement which will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ending September 30, 2025.


    Item 9.01. Financial Statements and Exhibits.
    (d) Exhibits
    Exhibit No.Description
     
    99.1
    Press Release, dated September 2, 2025.
    104Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
    Date: September 2, 2025
    ARROWHEAD PHARMACEUTICALS, INC.
      
    By:/s/ Daniel Apel
     Daniel Apel
     Chief Financial Officer

    Get the next $ARWR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARWR

    DatePrice TargetRatingAnalyst
    6/5/2024$31.00Neutral
    Goldman
    12/4/2023$29.00Buy
    BofA Securities
    9/19/2023$33.00Neutral
    Citigroup
    7/21/2023Outperform
    TD Cowen
    5/12/2023$40.00Outperform → Market Perform
    SVB Securities
    4/26/2023$80.00Outperform
    SMBC Nikko
    4/12/2023$21.00 → $35.00Market Perform → Outperform
    SVB Securities
    3/21/2023$27.00Mkt Perform
    Bernstein
    More analyst ratings

    $ARWR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Arrowhead with a new price target

    Goldman initiated coverage of Arrowhead with a rating of Neutral and set a new price target of $31.00

    6/5/24 7:11:50 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities initiated coverage on Arrowhead with a new price target

    BofA Securities initiated coverage of Arrowhead with a rating of Buy and set a new price target of $29.00

    12/4/23 7:19:37 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Arrowhead with a new price target

    Citigroup initiated coverage of Arrowhead with a rating of Neutral and set a new price target of $33.00

    9/19/23 7:26:13 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARWR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

    - Upon closing, Arrowhead will receive an upfront payment of $200 million - Novartis will receive an exclusive worldwide license to ARO-SNCA, Arrowhead's preclinical stage siRNA therapy for the treatment of synucleinopathies, such as Parkinson's Disease, plus additional collaboration targets Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced a global licensing and collaboration agreement with Novartis for ARO-SNCA, Arrowhead's preclinical stage siRNA therapy against alpha-synuclein for the treatment of synucleinopathies, such as Parkinson's Disease, and for other additional collaboration targets that will utilize Arrowhead's proprietary Targeted RNAi Molecule (TRiM™) platform

    9/2/25 7:30:00 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences

    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it is scheduled to participate in the following upcoming events: European Society of Cardiology (ESC) Congress 2025 – August 29 - September 1, 2025 Title: A Randomized, Placebo-controlled Phase 3 Study of Plozasiran in Patients With FCS: Interim Analysis of Open Label Extension of PALISADE at 1 Year Date/Time: August 30, 2025, 5:15 pm CET Type: Moderated Poster Presentation Title: Safety and Efficacy of Zodasiran, a Hepatic siRNA Targeting ANGPTL3, in Mixed Hyperlipidemia Patients: 2 Year Open Label Extension (OLE) Results from ARCHES-2 Date/Time: August 31, 2025, 8:15 am CET Presenter: Robert Rosenson Type: Moderated

    8/27/25 7:30:00 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

    - Arrowhead has elected to receive approximately $50 million worth of Arrowhead common stock from Sarepta, which will be placed into treasury and reduce the number of Arrowhead shares outstanding - The remainder of the recently earned $100 million milestone, or approximately $50 million, will be received in cash - Sarepta's remaining holdings of Arrowhead stock were sold today in a separate negotiated block trade Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has elected to receive approximately $50 million worth of Arrowhead common stock and approximately $50 million in cash from Sarepta Therapeutics, satisfying the payment of a $100 million milestone owed to A

    8/13/25 4:10:00 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARWR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lu Hongbo bought $82,990 worth of shares (3,000 units at $27.66), increasing direct ownership by 10% to 33,680 units (SEC Form 4)

    4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

    3/20/24 7:06:58 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARWR
    SEC Filings

    View All

    Arrowhead Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)

    9/2/25 4:02:33 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Arrowhead Pharmaceuticals Inc.

    SCHEDULE 13D/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

    8/15/25 5:28:19 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Arrowhead Pharmaceuticals Inc.

    SCHEDULE 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

    8/14/25 7:07:30 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARWR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Hamilton James C sold $375,000 worth of shares (15,000 units at $25.00), decreasing direct ownership by 6% to 247,122 units (SEC Form 4)

    4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

    9/4/25 5:37:01 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Hamilton James C sold $200,000 worth of shares (10,000 units at $20.00), decreasing direct ownership by 4% to 262,122 units (SEC Form 4)

    4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

    8/15/25 5:59:02 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Apel Daniel Joseph claimed ownership of 101,200 shares (SEC Form 3)

    3 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

    8/12/25 5:49:57 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARWR
    Leadership Updates

    Live Leadership Updates

    View All

    Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that, effective May 13, 2025, Arrowhead's Chief Financial Officer, Ken Myszkowski, will retire after 16 years of service to the company and will be succeeded by Daniel Apel, who has been appointed as the company's new Chief Financial Officer. Mr. Myszkowski will continue to serve as an employee adviser to assist and facilitate an effective transition. "Ken has been a valuable member of the Arrowhead team, and he retires at a time of great financial strength for the company. The finance organization that Ken built over the years is very capable and provides strong support to our ambitious development and commercialization plans.

    4/15/25 4:00:00 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600

    NEW YORK, Jan. 22, 2025 /PRNewswire/ -- Guidewire Software Inc. (NYSE:GWRE) will replace Arrowhead Pharmaceuticals Inc. (NASD: ARWR) in the S&P MidCap 400, and Arrowhead Pharmaceuticals will replace Barnes Group Inc. (NYSE:B) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, January 27. S&P 500 constituent Apollo Global Management Inc. (NYSE:APO) is acquiring Barnes Group in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector January 27, 2025 S&P MidCap 400 Addition Guidewi

    1/22/25 5:54:00 PM ET
    $APO
    $ARWR
    $B
    Investment Managers
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Turnstone Biologics Appoints William Waddill to its Board of Directors

    SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. "I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone," said Sammy Farah, M.B.A.,

    4/16/24 9:00:00 AM ET
    $ANNX
    $ARWR
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ARWR
    Financials

    Live finance-specific insights

    View All

    Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

    - Arrowhead has elected to receive approximately $50 million worth of Arrowhead common stock from Sarepta, which will be placed into treasury and reduce the number of Arrowhead shares outstanding - The remainder of the recently earned $100 million milestone, or approximately $50 million, will be received in cash - Sarepta's remaining holdings of Arrowhead stock were sold today in a separate negotiated block trade Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has elected to receive approximately $50 million worth of Arrowhead common stock and approximately $50 million in cash from Sarepta Therapeutics, satisfying the payment of a $100 million milestone owed to A

    8/13/25 4:10:00 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

    - Conference Call and Webcast Today, August 7, 2025, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is hosting a conference call today, August 7, 2025, at 4:30 p.m. ET to discuss the results. "Arrowhead continues to achieve strong execution in discovery, clinical and regulatory, and business development. Our pipeline has become quite mature, with four Arrowhead discovered candidates currently in pivotal Phase 3 studies. In addition, our commercial buildout is designed to make us launch ready on day one, should plozasiran receive regulatory approval on the November 18, 2025

    8/7/25 4:01:00 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results

    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on August 7, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 third quarter ended June 30, 2025. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at https://register-conf.media-server.com/register/BI3955ca6732974874b0bc0ac323811a7f. Once registered, you w

    7/21/25 4:01:00 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARWR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Arrowhead Pharmaceuticals Inc.

    SC 13G - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

    11/14/24 9:38:25 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Arrowhead Pharmaceuticals Inc.

    SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

    10/16/24 9:15:20 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Arrowhead Pharmaceuticals Inc. (Amendment)

    SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

    4/10/24 2:03:52 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care